Clinical trial Recruiting at 1 site Observational Ages 40 and up

Improving early diagnosis of dementia in primary care

Official title: The Swedish BioFINDER - Primary Care Study

Run by Skane University Hospital · NCT06120361 · Data updated 2026-11-12

This study is trying to find better ways to diagnose Alzheimer's and other memory problems early in people visiting their primary care doctors.

More Alzheimer Disease trials

Quick facts

Study typeObservational
Ages40 Years and up
SexAll
Enrollment1200 (estimated)
SponsorSkane University Hospital
Academic / other
Locations1 site (Malmö)
StatusRecruiting
StartedJanuary 1, 2020
Main results expectedDecember 31, 2028
Study endsDecember 31, 2028
Registry record updatedApril 6, 2026
Trial IDNCT06120361 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals aged 40 and older experiencing cognitive symptoms such as memory complaints or other cognitive difficulties.

Probably not a fit

Patients who have already been diagnosed with dementia or have cognitive impairment due to acute conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to enhance the diagnostic accuracy of Alzheimer's disease and cognitive impairment in primary care settings. It focuses on recruiting diverse patients with subjective cognitive decline, mild cognitive impairment, and mild dementia. The study will evaluate cognitive tests, blood-based biomarkers, and brain imaging methods to facilitate early diagnosis and improve patient management. By comparing traditional and novel cognitive screening tools, the study seeks to identify the most effective methods for early detection in primary care.

Why it matters

Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of dementia, improving patient care and treatment outcomes.

How similar studies have gone: Other studies have shown promise in using blood biomarkers and cognitive tests for early diagnosis of dementia, indicating a potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. The patient seeks medical help because of cognitive symptoms experienced by the patient and/or informant OR The general practitioner suspects a progressive neurodegenerative disorder including, but not limited to, Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration or subcortical vascular cognitive impairment.
2. The main symptom is usually memory complaints, but could also be executive, visuo-spatial, language, or attention complaints.
3. Age ≥40 years
4. Subjective cognitive decline, mild cognitive impairment or mild dementia

Exclusion Criteria:

1. Already diagnosed dementia
2. Significant unstable systemic illness or organ failure that makes it difficult to participate.
3. Current significant alcohol or substance misuse.
4. Refusing investigation at the Memory clinic
5. Cognitive impairment with acute onset due to stroke
6. The cognitive impairment can with certainty be explained by another condition or disease such as significant anemia, infection, severe sleep deprivation, psychotic disorder, moderate-severe depression, alcohol abuse etc.

Where it's running

  • Primary care centers in Region Skåne
    Malmö, Sweden
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.